New research reveals that patients who stop using popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a major medical journal demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"People using these treatments must be cognizant of the danger of quick rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass within about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that people who lose weight through lifestyle changes alone generally have a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Nutrition scientists suggest the mechanism of the drugs is key to understanding the amplified weight return.
The injections mimic a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
Health authorities suggest the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the significant potential of weight regain, the therapy should be considered long-term.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the long-term nature of excess weight," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the medication report a intense return of hunger.
"It felt as if something activating and you become starving," recalled an individual.
This difficulty is compounded if users have not developed permanent lifestyle or habit changes during treatment.
Growing Interest
Figures indicate that millions of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while these medications are potent agents for weight loss, they are not a standalone fix and long-term success relies on ongoing behavioural management.
